A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Everolimus (Primary)
Indications Adenocarcinoma; Gastric cancer; Intestinal cancer; Oesophageal cancer
Focus Therapeutic Use

22 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
27 Jun 2013 Planned end date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
02 Nov 2012 Planned end date changed from 1 Sep 2011 to 1 Jul 2013 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com